MRUS - Merus N.V. Price/Earnings to Growth Multiple

Symbol and logo of brand Merus N.V. (MRUS)

The success of Merus N.V. (MRUS) is based on FDA approval of new antibodies and patent protection. The PEG ratio demonstrates the current market value, while the 0.00 value indicates the asset's status. The company's model relies on outsourcing production and testing. Financial stability is supported by substantial cash reserves and payments from a strategic partner.

MRUS Merus Corp Price/Earnings to Growth Ratio (07/04/2022 - 01/10/2026)

Metric breakdowns and analytics for Merus N.V. (MRUS)

- share price and consensus valuation forecast:
Price Performance Chart Merus NV|MRUS - Consensus Target
- market capitalization statistics:
Market Valuation Merus Corp|MRUS - Total Company Value
- book value of equity indicators:
Net Asset Value per Share Merus|MRUS - Company Book Value|Market Cap to Net Assets Ratio merus.nl|MRUS - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Merus N.V.|MRUS - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio merus.nl|MRUS - Company Debts|Debt to Book Value Merus Corp|MRUS - Company Long-Term Debts|Short-Term Debt Merus|Intermediate Coverage Ratio merus.nl
- earnings and multiples data:
MRUS - Net Income|Projected Future Earnings Merus N.V.|MRUS - Price to Earnings Ratio|Market Cap to Projected Earnings Merus Therapeutics|MRUS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Merus Corp|MRUS - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Merus|MRUS - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months merus.nl|MRUS - Net earnings per share growth this year|Net earnings per share growth forecast for next year Merus N.V.
Fundamental company analysis:MRUS (Merus NV)
Mass-produced product of Merus NV

Investors assess asset quality through the ratio of market value to earnings growth, where values below one signal that a company is undervalued. By analyzing the PEG momentum indicator, the expert determines the balance of power between price and growth rates, which is critically important for Merus N.V. (MRUS) as it scales its pipeline of antibodies against solid tumors within the high-tech oncology sector.

Competing companies

IMMP (Immutep Ltd) - Growth-Adjusted Payback Ratio|Anixa Biosciences Inc - Price/Earnings to Growth Multiple|ATOS - Price/Earnings to Growth Multiple|CNTX - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Mersana Therapeutics|BriaCell (BCTX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple ESSA Pharma|QTI (QT Imaging Holdings Inc.) - PEG Multiple